[go: up one dir, main page]

AR108801A1 - Constructos del virus recombinante no patogénico de la enfermedad de marek que codifican antígenos del virus de la laringotraqueítis infecciosa y del virus de la enfermedad infecciosa de la bursa - Google Patents

Constructos del virus recombinante no patogénico de la enfermedad de marek que codifican antígenos del virus de la laringotraqueítis infecciosa y del virus de la enfermedad infecciosa de la bursa

Info

Publication number
AR108801A1
AR108801A1 ARP170101668A ARP170101668A AR108801A1 AR 108801 A1 AR108801 A1 AR 108801A1 AR P170101668 A ARP170101668 A AR P170101668A AR P170101668 A ARP170101668 A AR P170101668A AR 108801 A1 AR108801 A1 AR 108801A1
Authority
AR
Argentina
Prior art keywords
virus
infectious
marek
constructs
antigens
Prior art date
Application number
ARP170101668A
Other languages
English (en)
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59269985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR108801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR108801A1 publication Critical patent/AR108801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulga constructos del virus no patogénico multivalente recombinante de la enfermedad de Marek que codifican y expresan antígenos proteicos del virus de la laringotraqueítis infecciosa y un antígeno proteico del virus de la enfermedad infecciosa de la bursa, y sus métodos de uso en vacunas para aves de corral.
ARP170101668A 2016-06-17 2017-06-16 Constructos del virus recombinante no patogénico de la enfermedad de marek que codifican antígenos del virus de la laringotraqueítis infecciosa y del virus de la enfermedad infecciosa de la bursa AR108801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351471P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
AR108801A1 true AR108801A1 (es) 2018-09-26

Family

ID=59269985

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101668A AR108801A1 (es) 2016-06-17 2017-06-16 Constructos del virus recombinante no patogénico de la enfermedad de marek que codifican antígenos del virus de la laringotraqueítis infecciosa y del virus de la enfermedad infecciosa de la bursa

Country Status (12)

Country Link
US (3) US11596687B2 (es)
EP (2) EP3471766B1 (es)
JP (1) JP7046014B2 (es)
CN (1) CN109310750B (es)
AR (1) AR108801A1 (es)
BR (1) BR112018076021A2 (es)
DK (1) DK3471766T5 (es)
ES (1) ES2935643T3 (es)
HU (1) HUE061405T2 (es)
MX (1) MX2018015756A (es)
PL (1) PL3471766T3 (es)
WO (1) WO2017216287A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471766B1 (en) 2016-06-17 2022-12-14 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
BR112019012280A2 (pt) * 2016-12-14 2019-11-26 Boehringer Ingelheim Animal Health Usa Inc vetores recombinantes de hvt que expressam múltiplos antígenos de patógenos aviários e vacinas compreendendo os mesmos
MX2020003591A (es) 2017-10-12 2020-07-22 Intervet Int Bv Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.
BR112022004488A2 (pt) 2019-09-11 2022-05-31 Zoetis Services Llc Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos
CN116042709B (zh) * 2022-09-23 2025-01-14 广西大学 一种共表达马立克病病毒糖蛋白gC和gD的DNA疫苗构建方法
CN118325854B (zh) * 2024-06-12 2025-02-11 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 表达varIBDV VP2基因的重组Meq基因缺失马立克氏病病毒株及其构建方法与应用
CN118726484A (zh) * 2024-07-10 2024-10-01 华南农业大学 ILTV gD蛋白抗原表位表达盒及重组病毒和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121043A (en) 1985-09-06 2000-09-19 Syntro Corporation Recombinant herpesvirus of turkeys comprising a foreign DNA inserted into a non-essential region of the herpesvirus of turkeys genome
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5961982A (en) 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5834305A (en) 1985-09-06 1998-11-10 Syntro Corporation Attenuated herpesvirus, herpesvirus which include foreign DNA encoding an amino acid sequence and vaccines containing same
US5928648A (en) 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
EP0256092B1 (en) 1986-01-27 1998-04-08 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
GB8603341D0 (en) 1986-02-11 1986-03-19 Portapax Ltd Foam sheet
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
DE69016956T2 (de) 1989-12-04 1995-07-20 Akzo Nobel Nv Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
WO1992003554A1 (en) 1990-08-24 1992-03-05 Arthur Webster Pty. Ltd. Infectious laryngotracheitis virus vaccine
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US6913751B2 (en) 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
US6984728B2 (en) 1993-09-24 2006-01-10 Schering Corporation Recombinant infectious laryngotracheitis virus and uses thereof
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
US6632664B1 (en) 1997-10-03 2003-10-14 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
US6764684B2 (en) 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
CN1472315A (zh) * 2003-06-19 2004-02-04 中国农业科学院哈尔滨兽医研究所 表达喉气管炎或其它禽病毒基因重组禽痘病毒及其应用
JP2008228658A (ja) 2007-03-20 2008-10-02 Nippon Zeon Co Ltd 新規なプロモーター、これを有する組み換え七面鳥ヘルペスウイルス、及びこれを利用した家禽用ワクチン
US20080241188A1 (en) 2007-03-30 2008-10-02 Zeon Corporation Turkey herpesvirus vectored recombinant containing avian influenza genes
TWI468157B (zh) 2009-04-29 2015-01-11 Intervet Int Bv 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物
EP2629794B1 (en) 2010-10-18 2017-06-07 Intervet International B.V. Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
ES2700243T3 (es) * 2011-10-21 2019-02-14 Intervet Int Bv Construcciones del virus de la enfermedad de Marek recombinantes no patógenas que codifican antígenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad de Newcastle
US9096869B2 (en) 2011-10-21 2015-08-04 Intervet, Inc. Recombinant nonpathogenic MDV vector providing multivalent immunity
US9114108B2 (en) 2011-11-30 2015-08-25 Merial, Inc. Recombinant HVT vectors expressing antigens of avian pathogens and uses thereof
US9101598B2 (en) 2011-11-30 2015-08-11 Merial, Inc. Recombinant Gallid herpesvirus 3 (MDV serotype 2) vectors expressing antigens of avian pathogens and uses thereof
UA118651C2 (uk) 2011-11-30 2019-02-25 Меріал Інк Рекомбінантний вектор hvt, який експресує антигени патогенів птахів, та композиція, що його містить
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
US9555016B2 (en) 2013-06-10 2017-01-31 Covidien Lp Lytic agents for use in treating intravascular clots
EP2845904A1 (en) 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
CN103589693B (zh) * 2013-11-13 2016-02-03 江苏省农业科学院 一种表达ibdv vp2和法氏囊素三肽嵌合蛋白重组火鸡疱疹病毒
AR103245A1 (es) 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
US10537628B2 (en) 2015-08-10 2020-01-21 The Texas A&M University System Recombinant turkey herpesvirus vaccines and uses thereof
EP3471766B1 (en) * 2016-06-17 2022-12-14 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
JOP20190088A1 (ar) 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
BR112019012280A2 (pt) 2016-12-14 2019-11-26 Boehringer Ingelheim Animal Health Usa Inc vetores recombinantes de hvt que expressam múltiplos antígenos de patógenos aviários e vacinas compreendendo os mesmos
MX2020003591A (es) * 2017-10-12 2020-07-22 Intervet Int Bv Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.
EP3897709A1 (en) 2018-12-21 2021-10-27 Ceva Santé Animale Recombinant avian herpes viruses containing multiple foreign genes
US12440556B2 (en) 2020-06-15 2025-10-14 Zoetis Services Llc Genetically modified cell line for production of Marek's disease virus vaccine and methods of making and using the same
US20240252624A1 (en) 2020-06-17 2024-08-01 Teshome Mebatsion Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof

Also Published As

Publication number Publication date
PL3471766T3 (pl) 2023-04-11
WO2017216287A1 (en) 2017-12-21
US12514922B2 (en) 2026-01-06
RU2019101007A (ru) 2020-07-17
CN109310750A (zh) 2019-02-05
BR112018076021A2 (pt) 2019-04-02
DK3471766T5 (da) 2024-09-09
JP7046014B2 (ja) 2022-04-01
ES2935643T3 (es) 2023-03-08
JP2019517804A (ja) 2019-06-27
MX2018015756A (es) 2019-05-30
RU2019101007A3 (es) 2020-11-09
US20240123057A1 (en) 2024-04-18
EP3471766A1 (en) 2019-04-24
US20260021176A1 (en) 2026-01-22
US11596687B2 (en) 2023-03-07
EP3471766B1 (en) 2022-12-14
EP4215207A1 (en) 2023-07-26
CN109310750B (zh) 2022-08-12
US20220125915A1 (en) 2022-04-28
HUE061405T2 (hu) 2023-06-28
DK3471766T3 (da) 2023-03-13

Similar Documents

Publication Publication Date Title
AR108801A1 (es) Constructos del virus recombinante no patogénico de la enfermedad de marek que codifican antígenos del virus de la laringotraqueítis infecciosa y del virus de la enfermedad infecciosa de la bursa
PH12014500793A1 (en) Recombinant non-pathogenic marek`s disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
MX2020003591A (es) Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.
MX2021013355A (es) Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas.
CO2019006820A2 (es) Vectores recombinantes de hvt que expresan múltiples antígenos de patógenos de aves y sus usos
CL2020000192A1 (es) Anticuerpos anti-cd8 y usos de estos.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MX2019006340A (es) Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
EP3796927A4 (en) Shared antigens
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
CY1124218T1 (el) Ανασυνδυασμενοι αδενοϊικοi φορεις εμβολιων fmdv και χρησεις αυτων
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
UY35964A (es) Anticuerpos humanos para pd?1
MX421186B (es) Constructos de anticuerpos.
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
PE20180463A1 (es) Virus de la enteritis del pato y usos del mismo
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
CL2016003107A1 (es) Vacunas guiadas por anticuerpos y métodos de uso para generar respuestas inmunitarias maduras rápidas
CL2016001906A1 (es) Vacunas contra el reovirus aviar.
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.